Immunome (IMNM) Q1 2024 Earnings
IMNM·Reported May 14, 2024·Before market open
Immunome reported Q1 2024 revenue of $1.0M, missed analyst consensus of $2.8M by $1.8M. Diluted EPS came in at $-0.34, beat the $-0.80 consensus by $0.46.
Revenue
$1.0Mmissed by $1.8M
Consensus: $2.8MDiluted EPS
$-0.34beat by $0.46
Consensus: $-0.80
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Immunome's Q1 2024 earnings report.
Immunome (IMNM) reported Q1 2024 earnings on May 14, 2024 before market open.
Immunome reported revenue of $1.0M and diluted EPS of $-0.34 for Q1 2024.
Revenue missed the consensus estimate of $2.8M by $1.8M. EPS beat the consensus estimate of $-0.80 by $0.46.
You can read the 10-Q periodic report (0001558370-24-008066) directly on SEC EDGAR. The filing index links above go to sec.gov.